Craneware Share Discussion Threads

[nephie] 22/8/2010 20:02

Craneware plc is engaged in the development, licensing and post contract support of computer software for the healthcare industry. Craneware's products are divided into three product families, with the Craneware Business Solutions Group and Decision Dashboard spanning across all three families. Strategic Pricing Solutions include Patient Charge Estimator, Comparative Pricing Modules, Fee Schedule Modules and Pricing Policy Analysis Modules. Supply Management Solutions include Pharmacy ChargeLink and Supplies ChargeLink. Revenue Cycle Solutions includes Chargemaster Toolkit, Chargemaster Corporate Toolkit, Chargemaster Toolkit-CAH, Bill Analyzer, Online Reference Toolkit, Interface Scripting Module and Physician Revenue Toolkit/Physician Management Toolkit. Craneware Business Solutions Group includes services, which assist organizations. Decision Dashboard is a software, which provides decision makers with actionable financial information by monitoring performance indicators.

Craneware Plc (LON:CRW), the American company the develops automated revenue integrity systems for the US healthcare market, is set to unveil figures in line with expectations when it announces its full year results to June on September 3. The total value of contracts signed during the year will be the highest in the company's history, increasing by over 25% against 2009's $43.2m. Craneware credits this growth to an increased product range and stronger partner relationships, supported by favourable conditions in the US healthcare market. The majority of this revenue will, however, be recognised in future periods in accordance with the company's annuity revenue model, adding to its already high visibility of future revenues.

[andy] 22/2/2010 17:31

New article

[wjccghcc] 22/2/2010 10:27

Didn't get that from the statement. All they said was:

"In conjunction with the growth plans described above, the Board continues to
assess potential acquisition opportunities in line with our stated M&A policy."

With $27mm net cash and highly predictable revenues for the next 3-4 years, I doubt they'd need to tap shareholders unless it was a very large acquisition.

Results looked ahead to me with a 20% increase in EPS despite them now paying a normal tax rate vs 3% forecasted increase for the full year.

I see them being taken out by a US firm at some point though with 33% in director's hands, would need to be an agreed transaction.

[azalea] 22/2/2010 09:49

Looking to make an acquisition and tap shareholders to help fund it. Hmmn!

[paved] 22/2/2010 09:12

Craneware poised to keep delivering significant returns

[aim_trader] 19/2/2010 16:25

"Execution Noble initiates Craneware coverage with 'buy' recommendation ahead of results...

Execution Noble initiated coverage of Craneware (AIM: CRW) with a "buy" rating today, commenting that while the US healthcare focused vendor was trading at a significant premium, the current share price scribed little value to new contract signings."

[investinggarden] 19/1/2010 12:26

Reduce recommendation from Growth Company Investor

[pelleeds1980] 22/12/2009 10:09

I see the US healthcare reforms are taking shape I think this will be strong in 2010

[leluot2] 22/12/2009 08:22

Thats better. I like the gathering momentum reference. Could be a very positive update in January. Not the time to sell surely?

[leluot2] 15/12/2009 09:04

too quiet. no volume whatsoever. what happened to news of possible acquisitions?

[wjccghcc] 30/11/2009 07:53

Um, there was the AGM statement 10 days ago.

[leluot2] 29/11/2009 20:42

Would think some news is overdue. Needs something to put some life back into the market.

[pelleeds1980] 01/10/2009 15:01

From the latest results

Financial Highlights


* Record levels of contracted sales in the year totaling $43.2m (FY08: $25.7m),
68% up on the previous year, contributing to:
* 23% increase in revenues to $23.0m (FY08: $18.7m)
* 51% increase in future revenues under contract to $60.1m (FY08:$39.9m)

* Profit before share based payments, depreciation and amortisation increased 29%
to $5.8m (FY08: $4.5m)
* Profit before taxation increased by 40% to $5.9m (FY08: $4.2m)
* Cash position increased 24% to $26.1m (FY08 $21.1m)
* Basic EPS increased to $0.18 (FY08: $0.14) and diluted to $0.17 (FY08: $0.13)
* Final dividend proposed of 2.9p (4.77 cents) per share giving a total dividend
for the year of 4.7p (7.43 cents) per share (FY08: 3.1p (4.96 cents) per share)



Operational Highlights


* New products lines contributed $10.1m (23%) to total contracted sales during the
year
* Extended market reach through partnership deals with Premier, Amerinet and Perot
* Signed significant reseller agreement with McKesson Corporation post year-end
* Accelerated investment in sales and marketing activities
* Proposed US Healthcare reforms trend towards increased regulation and new market
opportunities



Keith Neilson, CEO of Craneware commented, "The US healthcare system is
currently undergoing an unprecedented level of change and public scrutiny. This,
combined with the global economic downturn means healthcare organisations are
experiencing extraordinary levels of fiscal and legislative pressure. Craneware
continues to invest in the development and deployment of software to help manage
these pressures and we believe that our market leading position and reputation
within the industry, combined with our strong business fundamentals, leaves us
well positioned to serve this growing market demand."

[leluot] 25/9/2009 07:56

"This contract with one of the leading healthcare organisations in the US, won following a competitive tendering process, underlines our market-leading position and further endorses the quality of our software and customer support. Additionally, the long-term nature of the contract adds to our significant amount of future revenue under contract, giving us a high-level of confidence in the ongoing growth of Craneware."

Continues to make great progress! Maybe some acquisition news next.

[barnesian] 21/9/2009 08:35

Altom - You are probably right. He just needed the readies. He had 145,000 shares and sold 10,000 of them at about £3 each.

[altom] 20/9/2009 17:50

The Director who sold - how many does he have left? £30,000 does not go far these days. Could be a daughter's wedding, new boat, Harley Davison, enlargement to house, wife or girl-friend, whatever ?

[barnesian] 18/9/2009 16:09

Yes - that's good news and bad news. Good that the price didn't crack. Bad that a director is selling. I assume it isn't because of any bad news to come but just an opportunity for him to take some profit at a high price. Who knows? We'll see.

[leluot] 18/9/2009 11:56

I see one Director sold 10,000 shares yesterday and today! Must have been the only one selling then - probably needed some pocket money!!!

Price steady despite this large sell - so Barnesian - it can be done without doing any harm!!

Expect some positive news soon - IMO

[leluot] 16/9/2009 14:58

Fair comment Barnesian but I think there could well be further buying interest in the near future. Even after a few sells today the share price continued up.
Strange a Scottish based company selling exclusively to the US! I think we could get a few pleasant surprises during the next six months so a temporary pull back would not worry me - although I dont think it will happen.
There should be more interest in this company. As you said it is a cracking good company with a splendid track record!

I also see Techinvest included CRW in its Second Half Best Buys. Dont normally follow recommendations from magazines but Techinvest is an excellent judge of young and promising tech companies - good to have their interest and support!

[barnesian] 16/9/2009 14:20

I think this is a cracking good company. It is tightly focused on the US healthcare market. It has very high margins. It is growing at a consistent 25% pa. It has excellent visibility of revenue and a pipeline of new products. It is sitting on a cash mountain of more than one year's revenue. It should have a very high rating and it does - a price today of 280p on eps of 10.3p is a P/E rating of 27 times.

That is an extraordinarily high rating for an AIM company. It may go even higher based on thin trading by small traders following the share up. I'd be tempted to take some profit at this stage

My fear is that if and when the small buying dries up (no share goes up for ever)or someone tries to take profit on a largish stake then any fall could be just as dramatic and overshoot on the downside.

It isn't a concern or criticism of the company. I think it is first class. It is just an observation, for what it's worth, on the latest run up of the share price and its fragility. But make up your own mind. I don't want to pour cold water on the party.

[leluot] 16/9/2009 14:02

I dont know this share well but guess there are not many shares available- market makers may well be short. The Obama stimulus programme should give a very favourable kick to the bottomline here and I believe there is considerable scope for a continued re-rating.

Fingers crossed - recent outlook statement also looked very confident. I certainly wouldnt be selling!!

[wjccghcc] 16/9/2009 13:55

Yup. I added on the results at 240p. The Mckesson agreement is likely to provide a large boost to their market share.

[leluot] 16/9/2009 13:43

Why would you want to get out of this share?
The future looks extremely bright for US Healthcare.
This could be the start of a considerable re-rating.

What are you fears Barnesian?